GSK To Sell Wellbutrin In US To Biovail For $510M
GlaxoSmithKline PLC said Wednesday it had agreed to sell rights to commercialize the antidepressant Wellbutrin XL in the U.S. to a subsidiary of its Canadian partner Biovail Corp. for $510 million....To view the full article, register now.
Already a subscriber? Click here to view full article